Invivyd (IVVD) announced the discovery and advancement of VMS063, a novel, potentially first- and best-in-class monoclonal antibody candidate for the treatment and prevention of measles. The company said VMS063 targets the measles fusion protein and has demonstrated highly potent in vitro neutralization of the measles virus across relevant lineages. Invivyd has begun IND-enablement and regulatory outreach to support rapid development, with a target of IND readiness in late 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd Advances COVID-19 Program and Launches Measles Antibody
- Invivyd Earnings Call Highlights Pivotal Trial Momentum
- Invivyd: Accelerating PEMGARDA Uptake and Strong Cash Runway Position VYD2311 as a De‑Risked Growth Catalyst
- Invivyd: Late‑Stage COVID-19 Antibody Progress and Solid Fundamentals Support Buy Rating
- Invivyd Advances VYD2311 With Key Phase 3 Alignments